Mar 11, 2021 7:10am EST Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
Feb 11, 2021 7:15am EST Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
Jan 15, 2021 6:30am EST Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
Jan 12, 2021 7:00am EST Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
Dec 22, 2020 6:30am EST Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
